Fragment-based drug discovery as alternative strategy to the drug development for neglected diseases.

about

Innovation in neglected tropical disease drug discovery and development.

P2860

Q55459515-F43D16A4-68DC-4DC5-9D36-39210E62B277

P2860

Fragment-based drug discovery as alternative strategy to the drug development for neglected diseases.

Item

http://www.wikidata.org/entity/Q36382655

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Fragment-based drug discovery ...... opment for neglected diseases.

@ast

Fragment-based drug discovery ...... opment for neglected diseases.

@en

type

Item

label

Fragment-based drug discovery ...... opment for neglected diseases.

@ast

Fragment-based drug discovery ...... opment for neglected diseases.

@en

prefLabel

Fragment-based drug discovery ...... opment for neglected diseases.

@ast

Fragment-based drug discovery ...... opment for neglected diseases.

@en

P1476

Fragment-based drug discovery ...... lopment for neglected diseases

@en

P2093

Drielli Gomes Vital-Fujii

http://www.w3.org/2001/XMLSchema#string

Glaucio Monteiro Ferreira

http://www.w3.org/2001/XMLSchema#string

Juliana da Fonseca Rezende E Mello

http://www.w3.org/2001/XMLSchema#string

Renan Augusto Gomes

http://www.w3.org/2001/XMLSchema#string

P2860

The development of drugs for treatment of sleeping sickness: a historical review

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Applications of (19)F-NMR in Fragment-Based Drug Discovery

Rational approaches to improving selectivity in drug design

Recent developments in fragment-based drug discovery

One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening

Entropic contribution to the linking coefficient in fragment based drug design: a case study

Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design

Optimization of a pyrazole hit from FBDD into a novel series of indazoles as ketohexokinase inhibitors

Using a Fragment-Based Approach To Target Protein-Protein Interactions

P304

1067-1078

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CBDD.13030

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gustavo Henrique Goulart Trossini

P577

2017-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28547936

http://www.w3.org/2001/XMLSchema#string

Fragment-based drug discovery as alternative strategy to the drug development for neglected diseases.

about

P2860

P2860

Fragment-based drug discovery as alternative strategy to the drug development for neglected diseases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698